A clinical experience with Gengraf™ (Abbott cyclosporine) in de novo renal transplant recipients.

被引：0
|
作者：
Scandling, J
Rajagopalan, PR
Magee, J
Conti, D
Mendez, R
Bronson, D
Awni, W
Nabulsi, A
Hoffman, R
机构：
[1] Stanford Univ, Med Ctr, Palo Alto, CA 94304 USA
[2] Med Univ S Carolina, Charleston, SC 29425 USA
[3] Univ Michigan, Med Ctr, Ann Arbor, MI USA
[4] Albany Med Coll, Albany, NY 12208 USA
[5] Natl Inst Transplantat, Los Angeles, CA USA
[6] Abbott Labs, Abbott Pk, IL 60064 USA
来源：
TRANSPLANTATION | 2000年 / 69卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
184
引用
收藏
页码：S161 / S161
页数：1
相关论文
共 50 条
  • [21] Pharmacodynamic monitoring of de novo renal transplant recipients receiving mycophenolate and cyclosporine with a conversion from cyclosporine to Everolimus
    Nolting, Jochen
    Glander, Petra
    Gainer, Niels
    Naik, Marcel
    Seffin, Anett
    Mai, Marco
    Klupp, Jochen
    Neurnayer, Hans H.
    Reinke, Petra
    Budde, Klemens
    AMERICAN JOURNAL OF TRANSPLANTATION, 2008, 8 : 550 - 550
  • [22] Exposure to CsA, and not to everolimus, is associated with impaired renal function in de novo heart transplant recipients.
    Varnous, Shaida
    Livi, Ugolino
    Poncelet, Alain
    Delgado, Juan
    Vermes, Emmanuelle
    Li, Yulan
    Arizon, Jose
    AMERICAN JOURNAL OF TRANSPLANTATION, 2008, 8 : 346 - 346
  • [23] Elevated De Novo Donor Specific Antibody After Alemtuzumab Induction in Renal Transplant Recipients.
    Fabbri, K.
    Descourouez, J.
    Jorgenson, M.
    Redfield, R.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2016, 16 : 619 - 619
  • [24] Incidence and Factors Associated with De Novo DSA After BK Viremia in Renal Transplant Recipients.
    Patel, S.
    Kuten, S.
    Knight, R.
    Nguyen, D.
    Graviss, E.
    Gaber, A.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2016, 16 : 769 - 769
  • [25] Elevated de novo donor specific antibody after alemtuzumab induction in renal transplant recipients.
    Jorgenson, Margaret
    Fose, Jillian
    Redfield, Robert
    Fabbri, Kassandra
    PHARMACOTHERAPY, 2016, 36 (07): : E103 - E104
  • [26] De novo malignancies in renal transplant recipients: experience at a single center in China
    Wu, Bin
    Wang, Kai
    Mo, Chun-Ba
    Shen, Zhong-Yang
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2015, 8 (02): : 2911 - 2916
  • [27] The clinical impact of 1:1 conversion from Neoral to a generic cyclosporine (Gengraf) in renal transplant recipients with stable graft function
    Qazi, Yasir A.
    Forrest, Alan
    Tornatore, Kathleen
    Venuto, Rocco C.
    CLINICAL TRANSPLANTATION, 2006, 20 (03) : 313 - 317
  • [28] Lower cyclosporine exposure increases the risk for sub-clinical rejection in renal transplant recipients.
    Barama, AA
    Yilmaz, S
    Gough, J
    Murphy, GF
    Yilmaz, A
    McKenna, R
    Sepandj, F
    Benediktsson, H
    TRANSPLANTATION, 2000, 69 (08) : S225 - S225
  • [29] Cyclosporine increases soluble P-selectin in renal transplant recipients.
    Schrama, YC
    van Dam, T
    Fijnheer, R
    Hene, RJ
    Rabelink, TA
    TRANSPLANTATION, 2000, 69 (08) : S221 - S221
  • [30] Cinacalcet influence the pharmacokineties of tacrolimus but not cyclosporine a in stable renal transplant recipients.
    Falck, Pal
    Vethe, Nils Tore
    Asberg, Anders
    Midtvedt, Karsten
    Bergan, Stein
    Reubsaet, Jan Leo Egge
    Holdaas, Hallvard
    AMERICAN JOURNAL OF TRANSPLANTATION, 2007, 7 : 535 - 535
12345